Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Trading Report for (FRX). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Market Edge
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Forest Laboratories, Inc. Issues FY 2013 EPS Guidance Below Analysts' Estimates
Forest Laboratories, Inc. announced that for fiscal 2013, it expects diluted earnings per share (EPS) to be in a range of $0.90 to $1.05 including acquisition related amortization, the estimated impact of increased investments for marketing to support the new product launches of aclidinium and linaclotide which expect to launch during the fourth calendar quarter of 2012, the continued launches of Teflaro, Daliresp and Viibryd and research and development to support the ongoing progress of late stage product development pipeline. According to I/B/E/S Estimates, analysts were expecting the Company to report EPS of $1.08 for fiscal 2013.
Latest Developments for Forest Laboratories Inc
- Almirall SA and Forest Laboratories Inc Announces Positive Phase III Combo Results from its Second Study for Aclidinium and Formoterol
- Forest Laboratories Inc Issues FY 2014 Guidance; Revenue Guidance Below Analysts' Estimates
- Almirall SA And Forest Laboratories Inc Announces Positive Phase III Study Results For Aclidinium And Formoterol Combination In COPD
- Forest Laboratories Inc Sees FY 2013 EPS Guidance At Low End Of Prior Range; Revises FY 2013 Revenue Guidance To A Range In Line With Analysts' Estimates
Latest Key Developments in Pharmaceuticals
- Herbalife Ltd Engages PricewaterhouseCoopers LLP As Auditors
- Drug regulator to probe Ranbaxy Laboratories Ltd's records, approvals in India-Business Standard
- Drug Regulator To Probe Ranbaxy Laboratories Ltd's Records, Approvals In India-Business Standard
- Baxter International Inc Receives Marketing Authorization For Hyqvia In European Union
- Share this
- Link this
- Digg this
Follow Reuters